INNO-206 - CAS 1361644-26-9
Catalog number:
1361644-26-9
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C37H42N4O13
Molecular Weight:
750.75
COA:
Inquire
Targets:
Antibody-drug Conjugates
Description:
Aldoxorubicin, also known as INNO-206, is the 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity. Following intravenous administration, doxorubicin prodrug INNO-206 binds selectively to the cysteine-34 position of albumin via its maleimide moiety. Doxorubicin is released from the albumin carrier after cleavage of the acid-sensitive hydrazone linker within the acidic environment of tumors and, once located intracellularly, intercalates DNA, inhibits DNA synthesis, and induces apoptosis. Albumin tends to accumulate in solid tumors as a result of high metabolic turnover, rapid angiogenesis, hyervasculature, and impaired lymphatic drainage. Because of passive accumulation within tumors, this agent may improve the therapeutic effects of doxorubicin while minimizing systemic toxicity.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
Aldoxorubicin; DOXO-EMCH; INNO 206; INNO206
MSDS:
Inquire
1.Anti-myeloma effects of the novel anthracycline derivative INNO-206.
Sanchez E1, Li M, Wang C, Nichols CM, Li J, Chen H, Berenson JR. Clin Cancer Res. 2012 Jul 15;18(14):3856-67. doi: 10.1158/1078-0432.CCR-11-3130. Epub 2012 May 22.
PURPOSE: Doxorubicin has shown efficacy especially in combination treatment for the treatment of multiple myeloma; however, its side effects limit its use. INNO-206 is an albumin-binding prodrug of doxorubicin, which is released from albumin under acidic conditions. Because INNO-206 has not been previously evaluated in any hematologic malignancy, we determined its anti-multiple myeloma effects.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Antibody-drug Conjugates Products


CAS 863971-24-8 Mc-MMAE

Mc-MMAE
(CAS: 863971-24-8)

Mc-MMAE, a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate and is a protective group (maleimidocaproyl) -conjugated MMAE.

mDPR-Val-Cit-PAB-MMAE
(CAS: 1491152-26-1)

mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate that consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE).

CAS 1361644-26-9 INNO-206

INNO-206
(CAS: 1361644-26-9)

Aldoxorubicin, also known as INNO-206, is the 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with anti...

Acetylene-linker-Val-Cit-PABC-MMAE
(CAS: 1411977-95-1)

Acetylene-linker-Val-Cit-PABC-MMAE is an antibody drug conjugate that consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMA...

CAS 646502-53-6 VcMMAE

VcMMAE
(CAS: 646502-53-6)

VcMMAE is an antibody-drug conjugate (ADC) with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysoso...

CAS 151038-96-9 Aldoxorubicin

Aldoxorubicin
(CAS: 151038-96-9)

Aldoxorubicin, also known as INNO-206,  is the 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with anti...

CAS 1401963-17-4 Vc-MMAD

Vc-MMAD
(CAS: 1401963-17-4)

Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload and antibody drug conjugate. For comparison purposes, the ADC A1 -mc-MMAD and/or ...

Fmoc-Val-Cit-PAB-MMAE
(CAS: 1350456-56-2)

Fmoc-Val-Cit-PAB-MMAE is an antibody drug conjugate contained Fmoc-Val-Cit-PAB and MMAE and probably have antineoplastic activity.

CAS 1401963-15-2 Mc-MMAD

Mc-MMAD
(CAS: 1401963-15-2)

For comparison purposes, the ADC A1 -mc-MMAD and/or A1 -vc-MMAD were used. The linker payload, mc-MMAD (6-maleimidocaproyl-monomethylauristatin-D) was conjugate...

Chemical Structure

CAS 1361644-26-9 INNO-206

Quick Inquiry

Verification code

Featured Items